WESTMINSTER, Colo.--(BUSINESS WIRE)--Allos Therapeutics, Inc. (Nasdaq: ALTH) today announced that the Company will present data from an in vitro study examining the potency of pralatrexate in colon, breast, ovarian, lung, prostate, and head and neck cancer cell lines at the upcoming American Association for Cancer Research 100th Annual Meeting to be held in Denver, CO on April 18 - 22.
